Secondary Prevention and Screening

Secondary prevention aims to detect chronic disease early — ideally in a pre-symptomatic or pre-clinical phase — so that treatment can be started while it is more effective and outcomes can be improved. Screening, the systematic application of a test to apparently healthy people to identify those likely to have or develop disease, is the principal tool of secondary prevention and is governed by a well-established set of appraisal criteria.

Definition

Secondary prevention comprises measures that identify and treat disease in an early or pre-symptomatic stage to halt or slow its progression; screening is the systematic testing of asymptomatic people to detect such early disease or its precursors.

Scope

This topic covers the logic of early detection, the Wilson and Jungner criteria for an acceptable screening programme, the performance measures used to evaluate screening tests, and the characteristic biases (lead-time and length-time bias, overdiagnosis) that complicate the interpretation of screening benefit. It is reference-educational and is not a recommendation for or against any specific screening test.

Core questions

• What conditions must be met for a screening programme to be worthwhile?
• How are screening tests evaluated, and why is mortality the preferred endpoint?
• How do lead-time bias, length-time bias, and overdiagnosis distort apparent benefit?
• When can early detection cause net harm rather than net benefit?

Key concepts

• Early detection
• Wilson and Jungner criteria
• Sensitivity and specificity
• Positive and negative predictive value
• Lead-time bias
• Length-time bias
• Overdiagnosis and overtreatment

Mechanisms

Screening works by detecting disease during the detectable pre-clinical phase, so that intervention begins earlier in the natural history than it would after symptoms appear. Whether earlier detection translates into better outcomes depends on whether earlier treatment is more effective. The value of a programme rests jointly on the test's accuracy (sensitivity and specificity), the prevalence of the condition (which drives predictive value), and the existence of an effective early treatment. Apparent benefit can be inflated by lead-time bias (survival measured from an earlier diagnosis appears longer without any true gain), length-time bias (screening preferentially catches slowly progressing cases), and overdiagnosis (detection of disease that would never have caused harm), all of which must be controlled — ideally through randomised trials with mortality endpoints.

Clinical relevance

Screening programmes for cancers and cardiometabolic risk are central activities of preventive health services, and the appraisal framework guides which programmes are offered. Understanding the biases of screening helps practitioners interpret programme statistics and communicate benefits and harms. This entry explains how screening is evaluated and does not recommend specific tests or intervals for any individual.

Epidemiology

Screening for chronic disease is most defensible where the condition is common, has a recognisable early stage, and has effective early treatment. Randomised evidence underpins some programmes — for example, the National Lung Screening Trial showed that low-dose CT screening reduced lung-cancer mortality in heavy smokers relative to chest radiography — while for other conditions the balance of benefit and harm remains contested. Overdiagnosis is now recognised as a material harm in several established screening settings.

Evidence & guidelines

The Wilson and Jungner principles, published by WHO in 1968, remain the foundational criteria for judging whether a screening programme should be introduced, and they continue to be cited and updated. Programme-specific recommendations are issued by national screening committees and preventive-services task forces and are based on randomised and observational evidence that varies in strength by condition.

History

Systematic screening expanded in the mid-twentieth century alongside the rise of chronic disease. Wilson and Jungner's 1968 WHO monograph codified the principles for deciding when screening is justified, and these criteria have anchored the field ever since. Subsequent decades brought large randomised screening trials and a growing recognition of overdiagnosis, which reshaped how the benefits and harms of early detection are weighed.

Debates

Overdiagnosis and the limits of early detection

More sensitive tests detect more abnormalities, some of which would never have progressed to cause symptoms or death; quantifying overdiagnosis and overtreatment, and weighing them against mortality benefit, is a central and unresolved challenge in evaluating screening.

Key figures

• James Maxwell Glover Wilson
• Gunnar Jungner

Seminal works

• wilson-jungner-1968
• nlst-2011

Frequently asked questions

What is the difference between screening and diagnosis?

Screening applies a test to apparently healthy people to sort out those who are more likely to have a condition; it is not itself a diagnosis. People who screen positive need further diagnostic evaluation to confirm or exclude disease.

Why can a screening programme do more harm than good?

Screening can cause harm through false positives and the anxiety and follow-up they trigger, and through overdiagnosis — detecting disease that would never have caused symptoms, leading to unnecessary treatment. A programme is only worthwhile when the benefits clearly outweigh these harms.